{"id":2198,"date":"2026-09-23T01:09:00","date_gmt":"2026-09-22T16:09:00","guid":{"rendered":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-23-glp1-discontinuation-cardiovascular-risk-en\/"},"modified":"2026-09-23T01:09:00","modified_gmt":"2026-09-22T16:09:00","slug":"2026-09-23-glp1-discontinuation-cardiovascular-risk-en","status":"publish","type":"briefing","link":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-23-glp1-discontinuation-cardiovascular-risk-en\/","title":{"rendered":"Two-year GLP-1 discontinuation linked to 22% higher relative cardiovascular risk in type 2 diabetes"},"content":{"rendered":"

2026-09-23 01:09 KST<\/strong><\/p>\n

The study included 132,551 new GLP-1 users with type 2 diabetes, reassigned treatment status every six months and compared three-year outcomes.<\/p>\n

Risk ratios were 1.04 after 0.5 years off, 1.14 after one year and 1.22 after two; veteran-heavy data and residual confounding limit personal predictions.<\/p>\n

What does 22% compare?<\/h2>\n

It is relative to a continued-use strategy and combines myocardial infarction, stroke and all-cause death. It is not a 22-percentage-point rise in an individual\u2019s absolute probability.<\/p>\n

Study design<\/h2>\n

US Veterans Affairs data from 2017\u20132023 included 132,551 new GLP-1 users and 201,136 sulfonylurea users. Prescriptions emulated a target trial; people were not randomly assigned.<\/p>\n

\"Two-year
This AI-generated image explains the topic; it is not a photograph of an actual event, observation or field site.<\/figcaption><\/figure>\n

Why caution?<\/h2>\n

Cost, side effects or worsening illness can cause discontinuation and also relate to risk. Adjustment cannot remove every such residual difference.<\/p>\n

What patients should do<\/h2>\n

Discuss side effects, cost, alternatives, dose and monitoring with the prescriber. This study does not establish benefits of self-directed continuation, restarting or tapering.<\/p>\n

Primary source and independent checks<\/h2>\n

BMJ Medicine \uc6d0 \uc5f0\uad6c<\/a><\/p>\n

Nature Reviews Endocrinology \ub3c5\ub9bd \uac80\ud1a0<\/a><\/p>\n

Axios \ucd5c\uadfc \ub3c5\ub9bd \uc124\uba85<\/a><\/p>\n

Read in other languages<\/h2>\n

\ud55c\uad6d\uc5b4<\/a> \u00b7 English<\/a> \u00b7 Espa\u00f1ol<\/a> \u00b7 \u65e5\u672c\u8a9e<\/a> \u00b7 Ti\u1ebfng Vi\u1ec7t<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A target-trial emulation in US veterans linked two years off GLP-1 receptor agonists with 22% higher relative risk of heart attack, stroke or death than continued use. It is observational evidence, not an instruction to continue or stop medication unaided.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"class_list":["post-2198","briefing","type-briefing","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing\/2198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing"}],"about":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/types\/briefing"}],"wp:attachment":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/media?parent=2198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}